Mineralys Therapeutics takes full ownership of lorundrostat IP from Tanabe Pharma

Mineralys Therapeutics entered into an agreement on October 27, 2026 to terminate its 2020 license agreement with Tanabe Pharma and assume full ownership of the intellectual property and know-how for lorundrostat. Mineralys retains commercial milestone obligations of up to $255 million in potential payments plus $10 million tied to a potential second indication.

Detected & updated continuously · Source: Nebula